In this video module, Program Director Nadia Harbeck and Patient Advocate Renate Haidinger discuss the importance of shared decision making throughout the course of a patient’s treatment, including the communication of risk, and decisions on testing, therapies and adverse event management.
Learning objectives
After completing this activity, you will be able to:
- Discuss best practice for communicating about recurrence risk and treatment options with those diagnosed with HR+/HER2- early breast cancer
- Integrate tools and guidance on shared decision making to ensure patient preference is a high priority when choosing the management strategy
Accreditation
When you have completed this activity you will be asked to fill in a short evaluation survey. Your feedback helps us to give you the best learning experience.
In support of improving patient care, this activity is accredited by North American Center for Continuing Medical Education (NACCME) for 0.25 AMA PRA Category 1 Credit(s)™. Should you wish to claim credits for this activity, please select “yes” in the evaluation survey when directed and download your certificate. Should you simply wish to provide us with valuable feedback, please select “no” when directed and submit your feedback.
Download the communication aid
Nadia and Renate’s conversation has been summarised into a practical communication aid, listing key considerations from both the clinician and patient point of view for shared decision making with HR+/HER2- early breast cancer patients.
Please select your preferred language to access the communication aid.
Sign up for new content alerts
Enter your email address below and we'll contact you as soon as new content is launched!
